We claim:

1. Monoclonal antibody which specifically binds to tumor rejection antigen precursor MAGE-1.

2. The monoclonal antibody of claim 1, designated MA454.

3. Hybridoma cell line which produces the monoclonal antibody of claim 1.

4. The hybridoma cell line of claim 3, wherein said monoclonal antibody is MA454.

5. Method for determining tumor rejection antigen precursor MAGE-1 in a sample, comprising contacting said sample with the monoclonal antibody of claim 1 and determining binding of said monoclonal antibody to a component of said sample as a determination of MAGE-1 in said sample.

6. The method of claim 5, wherein said monoclonal antibody is bound to a solid phase.

7. The method of claim 5, wherein said monoclonal antibody is labelled with a detectable label.

Sub
C1

8. Isolated, MAGE-1 tumor rejection antigen precursor.

2

9. The isolated MAGE-1 tumor rejection antigen precursor of claim 8, which is a glycoprotein having a molecular weight of about 46 kilodaltons as determined by SDS-PAGE.

3

10. The isolated MAGE-1 tumor rejection antigen precursor of claim 8, which is a recombinantly produced protein having a molecular weight of about 34.3 kilodaltons as determined by SDS-PAGE.

4

11. Isolated protein consisting of amino acids 57-219 coded for by nucleotides 3931-4761 of the nucleotide sequence of SEQ I.D. NO.: 1.

5

12. Isolated peptide selected from the group consisting of:

SEQ ID NO: 2,

SEQ ID NO: 3, and

SEQ ID NO: 4.

6

13. Immunogenic composition comprising at least one isolated glycoprotein ~~protein~~ of claim 9 and an adjuvant.

7

14. Immunogenic composition comprising at least one isolated protein of claim 10 and an adjuvant.

24

8

15. Immunogenic composition comprising at least one isolated protein of claim 11 and an adjuvant.

9

16. Immunogenic composition comprising at least one peptide of claim 12 and an adjuvant.

add col